Orchid Pharma Limited is an Indian pharmaceutical company headquartered in Chennai, Tamil Nadu. The company is engaged in the development, manufacture and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms, with a particular focus on antibiotics. It is best known for its expertise in cephalosporins and beta-lactam chemistry.
| Field | Details |
|---|---|
| Type | Public limited company |
| Industry | Pharmaceuticals |
| Headquarters | Chennai, Tamil Nadu, India |
| Founder | K. Raghavendra Rao |
| Products | Active pharmaceutical ingredients, finished dosage forms, antibiotics |
| Therapeutic focus | Cephalosporins, carbapenems, beta-lactam antibiotics |
| Listings | BSE, NSE |
Background
The company was founded by K. Raghavendra Rao and grew during the 1990s and 2000s into one of India's significant exporters of bulk antibiotics. Its operations cover fermentation-based and synthetic chemistry routes for antibiotic APIs, along with formulations manufacturing for sterile and oral dosage forms. Orchid's manufacturing facilities are located in Tamil Nadu, including sites at Alathur and Aurangabad, and have at various times been approved by international regulators including the United States Food and Drug Administration (USFDA), the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) and the World Health Organization.
Business segments
- Active pharmaceutical ingredients: manufacture and export of cephalosporin and other antibiotic APIs.
- Finished dosage forms: oral and sterile formulations, including injectables.
- Contract manufacturing: supply of antibiotic products to global pharmaceutical companies.
History
- The company was incorporated as Orchid Chemicals & Pharmaceuticals Limited and grew through investments in cephalosporin manufacturing capacity.
- In 2009–2010, Orchid divested its generic injectables business to Hospira, the United States–based specialty pharmaceutical company, in a major transaction that reshaped its product portfolio.
- The company subsequently rebranded as Orchid Pharma Limited, narrowing its focus to antibiotics and APIs.
- Owing to financial stress, Orchid Pharma was admitted to the corporate insolvency resolution process under the Insolvency and Bankruptcy Code, 2016.
- The resolution plan submitted by Dhanuka Laboratories Limited was approved by the National Company Law Tribunal, leading to a change in ownership and a restructuring of the company's operations.
Significance
Orchid Pharma has played a notable role in India's emergence as a major global supplier of antibiotic APIs, particularly in the cephalosporin segment. Its integrated manufacturing model, combining fermentation, chemical synthesis and formulations, made it one of the few Indian companies operating across the full antibiotic value chain. The insolvency and resolution of Orchid Pharma is also frequently cited as one of the early pharmaceutical-sector cases under India's Insolvency and Bankruptcy Code framework.
Related topics
- Pharmaceutical industry in India
- Cephalosporin
- Active pharmaceutical ingredient
- Insolvency and Bankruptcy Code, 2016
- Hospira
- Chennai
References
- Wikidata entity: Q7100279
- Filings and disclosures of Orchid Pharma Limited with the BSE and NSE.
- Orders of the National Company Law Tribunal relating to the corporate insolvency resolution of Orchid Pharma Limited.